转移
癌症研究
免疫系统
医学
免疫疗法
原发性肿瘤
免疫检查点
单克隆抗体
癌症
淋巴
神秘的
抗原呈递
抗原
抗体
免疫学
T细胞
病理
内科学
替代医学
作者
Peng Zheng,Jinrong He,Zhongqian Yang,Yuting Fu,Ying Yang,Weiran Li,Yiting Ding,Xu Yang,Yanbing Ma
出处
期刊:Small
[Wiley]
日期:2023-08-30
卷期号:19 (50)
被引量:2
标识
DOI:10.1002/smll.202302922
摘要
The notorious limitation of conventional surgical excision of primary tumor is the omission of residual and occult tumor cells, which often progress to recurrence and metastasis, leading to clinical treatment failure. The therapeutic vaccine is emerging as a promising candidate for dealing with the issue of postsurgical tumor residuals or nascent metastasis. Here, a flexible and modularized nanovaccine scaffold based on the SpyCatcher003-decorated shell (S) domain of norovirus (Nov) is employed to support the presentation of varied tumor neoantigens fused with SpyTag003. The prepared tumor neoantigen-based nanovaccines (Neo-NVs) are able to efficiently target to lymph nodes and engage with DCs in LNs, triggering strong antigen-specific T-cell immunity and significantly inhibiting the growth of established orthotopic 4T1 breast tumor in mice. Further, the combination of Neo-NVs and anti-PD-1 monoclonal antibody (mAb) produces significant inhibition on postsurgical tumor recurrence and metastasis and induces a long-lasting immune memory. In conclusion, the study provides a simple and reliable strategy for rapid preparing personalized neoantigens-based cancer vaccines and engaging checkpoint treatment to restore the capability of tumor immune surveillance and clearance in surgical patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI